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Creatinine measurements often yield false estimates of progression in
chronic renal failure. In 9 of 22 observation periods (lasting an average
of 15 months) in 17 patients with moderate to severe chronic renal
failure (GFR 4 to 23 mI/mm), rates of progression as estimated from the
linear regression on time of 24-hour creatinine clearance (b1) differed
significantly from rates of progression as estimated from the regression
on time of urinary clearance of ssmTcDTPA (b2), during all or part of
the period of observation, b1 exceeded b2 in four cases and was less
than b2 in the other five. Thus there were gradual changes in the
fractional tubular secretion of creatinine in individual patients, in both
directions. Owing to these changes, measurements of creatinine clear-
ance gave erroneous impressions of the rate or existence of progression
during all or a portion of the period of observation in nearly half of these
patients. In the 22 studies as a group, using the entire periods of
observation, b1 indicated significantly more rapid progression (by 0.18
0.06 mI/mm/month, P < 0.01) than did b2, and had a significantly
greater variance. Measurements of progression based on the rate of
change of reciprocal plasma creatinine (multiplied by an average rate of
urinary creatinine excretion in each study) were equally misleading,
even though less variable. We conclude that sequential creatinine
measurements are often misleading as measures of progression and
should, when feasible, be replaced by urinary clearances of isotopes in
following patients with chronic renal failure.
Creatinine measurements in plasma and urine have tradition-
ally been employed to assess the severity of chronic renal
failure and the rate of its progression. It has long been recog-
nized, however, that creatinine clearance exceeds glomerular
filtration rate (GFR) [1], owing to tubular secretion. Further-
more, the ratio of creatinine clearance (Car) to GFR varies with
the severity of renal insufficiency [2—4].
Nevertheless, there remains the possibility that the rate of
change of CCr might be an accurate reflection of the rate of
change of GFR. If this were the case, sequential measurements
of Ccr could be substituted for the more laborious sequential
measurements of GFR in following patients with chronic renal
failure.
Shemesh et al [4] made two measurements of inulin clearance
and CCr in patients with progressive chronic renal failure,
separated by intervals of 3 to 12 months, and found that both
C and reciprocal plasma creatinine ([Cr I]) suggested wors-
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ening by 29 to 33%, while in reality, GFR had fallen to almost
half of its original value. In patients whose GFR was improving,
creatinine measurements indicated improvement of only 12 to
13%, while GFR actually rose by 33%.
These authors also pointed out the frequency with which CCr
or plasma [Cr] alone will fail to detect the presence of chronic
renal failure. In a majority of patients with modestly reduced
GFR (40 to 80 mI/mm), both Ccr and plasma [Cr] were within
the range of normal. Others have reported similar findings [1—3,
5].
The purpose of the present study was to compare rates of
progression of chronic renal failure as assessed by sequential
measurements of urinary and plasma Cr with rates assessed
concurrently by sequential measurements of isotope GFR.
Urinary clearance rather than plasma clearance of the isotope
was measured, because we have found that plasma clearance
overestimates GFR (as reflected by urinary isotope clearance)
in patients with severe or moderately severe chronic renal
failure [6].
Methods
Seventeen patients were selected for study, 11 males and 6
females. Diagnoses were chronic glomerulonephritis (5), inter-
stitial or post-obstructive nephropathy (4), diabetic nephropa-
thy (4), arteriolar nephrosclerosis (1), polycystic kidney disease
(1), and unknown (2). All were being treated with a low protein
diet (0.3 g per kg ideal body weight) supplemented by either
essential amino acids or a mixture of amino acids and ketoacids
[7]. Three patients (M, R and S) were studied twice, once on
amino acids and once on ketoacids, and one patient (C) was
studied three times, once on amino acids and on two separate
periods while on ketoacids. Observation periods varied from 6
to 33 months (average 15 months). Isotope GFR was measured
bimonthly. Twenty-four hour Ccr was measured on the day
preceding the isotope GFR determination and usually one
additional time between GFR determinations. Thus the average
number of GFR determinations per study was 7 and the average
number of Cr determinations was 11.
The technique of isotope GFR determinations was as follows:
The subjects fasted the morning of the study. An oral water load
of 10 to 15 ml/kg was ingested to initiate diuresis. Throughout
urine collection periods, urine output was measured and an
equal volume of water was ingested. An intravenous injection
of 100 Ci of technetium-labeled diethylenetriamine penta-
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Urine flow, mi/minute
Fig. 1. Plots of residuals about the regression of GFR on time against
total urine flow during GFR measurement in patient L. Large negative
residuals are seen at flows of 1 ml per mm or less (A). When these are
deleted and the regression recalculated (B), the dependence of residuals
on urine flow disappears.
acetic acid (99mTc..DTpA) was administered. After 60 minutes,
three urinary collections of 30 to 45 minutes duration were
obtained. Venous blood samples were drawn via a heparin lock
before the first collection and following each voiding. Urinary
clearance of mTcDTPA were calculated for each collection
period as urine activity times urine flow divided by average
plasma activity. These values were then averaged for the three
collection periods.
99mTCDTPA was used immediately after preparation. Before
injection, radiochemical purity was evaluated within hours of
injection by thin-layer chromatography using acetone as a
solvent. Mean percent bound was 99.1% (range 97.8 to 99.7%).
Urine flow during GFR determination in these patients was
frequently relatively low, especially in those with more severely
reduced GFR, in whom flow rates under 1 ml per mm were
occasionally seen. Rather than exclude all GFR determinations
with flows under some arbitrary lower limit, we used a regres-
sion technique to identify retrospectively the lower limit of flow
to be accepted in individual patients. This was done by calcu-
lating flow in each study as total urine voided during the three
collection periods divided by total time elapsed. Residuals from
the linear regression of GFR on time in months were plotted
against urine flow calculated in this manner. In two studies (F
and L), these plots showed that flows below lower limits of 1 ml
per mm were associated with large negative residuals (Fig. 1).
Consequently these GFR determinations were rejected and the
regressions recalculated.1 In the other studies, there was no
lower limit of flow below which large negative residuals were
seen, and consequently no GFR values were rejected.
For the measurement of 24-hour creatinine clearance, urine
was stored during collection in the patients' refrigerators.
Creatinine was measured in the Johns Hopkins Hospital Chem-
istry Laboratory in urine and in plasma obtained the following
l The conclusions set forth below are not altered by the inclusion or
exclusion of these observations.
morning soon after the end of collection by an automated
method, using the Jaffe reaction, which includes chromogens
other than creatinine.
Least squares linear regression slopes of creatinine clearance
on time, Y1 = a + b1T, and of isotope GFR on time, Y2 = a2
• •
+ bIT, were calculated. In order to determine whether progres-
• .' • sion rates based on the slope of reciprocal plasma creatinine
were different from those based on isotope GFR, "creatinine'
clearances" (Y3) were also calculated, using a constant average
value for creatinine excretion in each study. This gives the same
slope as the slope of reciprocal plasma creatinine multiplied by
average creatinine excretion. The least squares linear regres-
sions of "creatinine' clearances", Y3 = a3 + b3T, were
calculated. The significance of the differences between b1 and b2
2 and between b2 and b3 was calculated by using a dummy
variable Z. Z = 0 for isotope GFR and Z = 1 for CCr. We then
fitted the data to the multiple regression equation Y = c1 + c2T
+ c3Z + c4ZT, where Y is either clearance in mi/mm, and T is
time in months. Then c1 = a2, c2 = b2, c3 = a1 — a2, and c4 =
b1 — b2. The significance of the coefficient c4 gives the signifi-
cance of the difference between the two slopes [81. When the
two slopes did not differ significantly, plots of both pairs of
clearances against time were examined visually to identify
subperiods during which significantly different slopes appeared
to be present, and these differences were then tested statisti-
cally as above. Within these subperiods, no clearances were
rejected. Computations were carried out using SAS software
(SAS Institute Inc., Cary, North Carolina, USA).
Results
Overall comparison of slope of creatinine clearance (b1) with
slope of isotope clearance (b2)
Mean b1 indicated significantly faster progression than b2, by
0.182 0.056 ml/min/month (P < 0.01 for paired comparison).
Mean b2 was —0.163 mI/mm/month. Thus, if b2 is accepted as
the true rate of change of GFR, b1 overestimates it by twofold,
on the average.
Average values for 0b1 and 0b2 were 0.167 and 0.102, respec-
tively, and were significantly different (P < 0.04) by Wilcoxon's
signed rank test [9]. Thus creatinine clearances, in our hands,
are less closely correlated with time than isotope clearances.
Obviously this result is critically dependent on the reliability of
urine collection as well as the analytical measurements em-
ployed.
Results in those studies in which b1 and b2 did not differ
significantly are summarized in Table 1.
Studies in which isotope clearances and creatinine clearances
indicate signJicantly different rates of progression
These are summarized in Table 2 and depicted in Figures 2
through 10. Discrepancies were seen in non-diabetic as well as
diabetic patients, and in those receiving amino acids as well as
ketoacids, thus making it unlikely that the results are attribut-
able to interference by ketones or ketoacids in the measurement
of creatinine. Subperiod progression rate differed significantly
from entire period progression rate in only one case.
Patient A, whose results are depicted in Figure 2, exhibits
significant (P < 0.025) improvement in creatinine clearance for
14 months, while isotope clearance remains essentially con-
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Table 1. Studies during which sequential creatinine clearances and isotope clearances did not yield significantly different estimates of
progression rate, b, during any part of observation period
Pt
dMean GFR
mi/mm Rxe
Isotope clearances
b
Creatinine clearances
N bN b
C 8.0 A 4 0.055 7 0,5l8" 0.151
C 6.6 K! 4 —0.056 0.095 9 —0.253 0.139
E 11.5 K 7 0,083 7 —0.336 0.242
G 7.8 A 5 —0.313 0.265 7 0.210
L 6.2 K 9 0.015 21 —0.059 0.030
M 4.4 A 10 —0.052" 0.016 14 —0.111" 0.039
M 3.8 K 4 +0.030 0.067 5 +0.155 0.099
0 6.5 K 12 —0.112 0.060 20 0.042
P 23.3 A 6 0.262 7 —1.153 0.960
S 14.2 A 7 0.50? 0.197 12 —0.344 0.176
S 10.8 K 4 +0.029 0.235 5 —0.244 0.269
U 5.9 A 5 —0.458" 0.107 8 0.256
W 7.2 A 7 —0.295 0.120 16 —0.539 0.122
x 8.9 6.5 —0.242 0.121 10.6 —0.384 0.210
a Significantly different from zero, P < 0.05
"Significantly different from zero, P < 0.025
C Significantly different from zero, P < 0.01
d Mean isotope clearance during period of study
C K = ketoacids, A = amino acids
Table 2. Studies during which sequential creatinine clearances and isotope clearances yield significantly different estimates of progression rate,
b, during all or part of observation period
Pt
hMean GFR
mi/mm Rx
SubperiocP Entire period
Isotope clearances Creatinine clearances Isotope clearances Creatinine clearances
N b ub N b o1, N b cr,, N b 7b
A 7.6 K 9 —0.045 0.044 15 +O.l77lC 0.061 13 —0.025 0.027 20 +0.038 0.038
B 4.0 K 5 0.097 7 +0.lOOC 0.082 6 0.068 9 —0.065 0.081
C 4.2 K2 3 +0.219 0.089 7 0,552b,f 0.133
D 4.7 K 10 +0.013 0.066 20 0.059
F 11.6 A 5 0.032 7 +0.046a 0.129 9 —0.154" 0.038 7 —0.016 0.065
H 3.9 K 12 0,060d 0.025 20 0.023
R 9.0 A 4 —0.526 0.171 3 0.025 5 —0.384 0.148 5 —1.11" 0.28
R 8.0 K 5 —0.101 0.134 7 —0.547 0.128 6 —0.103 0.088 9 —0.442" 0.114
T 20.2 A 9 +0.349e 0.122 12 0.141i 8.1 5.6 —0.267 0.096 7.8 —0.390 0.085 8.1 —0.048 0.075 12.1 —0.293 0.104
a Significantly different from slope of isotope clearance, P < 0.05
b Significantly different from slope of isotope clearance, P < 0.025
C Significantly different from slope of isotope clearance, P < 0.01d Significantly different from zero, P < 0.05
C Significantly different from zero, P < 0.025
Significantly different from zero, P < 0.01
Significantly different from entire period, P < 0.01
h Mean isotope clearance during period of study
K = ketoacids, A = amino acids
Subperiod: an interval within the entire period of observation during which a statistically significant difference in estimates of progression is
demonstrable (Methods)
stant. Thus the ratio of creatinine clearance to GFR increases
progressively. Eventually this trend stops, and the overall slope
of creatinine clearance as well as isotope clearance becomes
essentially zero.
Patient B, depicted in Figure 3, is progressing at a significant
rate (P < 0.05) as indicated by isotope clearances from month 4
onward, but creatinine clearances fail to show this progression
and in fact suggest improvement.
Patient C (Fig. 4) exhibits significant (P < 0.01) worsening
according to creatinine clearances, but no significant change in
isotope GFR.
Patient D, followed for 18 months, appears to be progressing
(P < 0.01) from creatinine clearances (Fig. 5), but isotope
GFR's are constant. Here the ratio of creatinine clearance to
GFR decreases progressively from approximately 2 to near
unity.
Patient F (Fig. 6) shows highly significant progression (P <
0.01) by isotope GFR's until month 18, but creatinine clear-
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Fig. 3. Clearance in patient B, plotted as in Figure 2. From April
(month 4) on, isotope GFR's show progression but creatinine clear-
ances do not.
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E
Months
Fig. 4. Clearances in patient C during second course of ketoacid
therapy, plotted as in Figure 2. Creatinine clearances indicate progres-
sion but isotope GFR's do not.
Months
Fig. 6. Clearances in patient F, plotted as in Figure 2. For the first half
of his course, creatinine clearances fail to exhibit progression, clearly
shown by isotope GFR.
10
Months
Fig. 7. Clearances in patient H, plotted as in Figure 2. The rate of
progression as estimated from creatinine clearances, —0.147 ml/minl
mo, is significantly faster than that indicated by isotope GFR's, —0.06
mI/mm/mo.
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Fig. 2. Sequential creatinine clearances (0) and isotope GFR's (U) in
patient A, plotted against calendar months beginning with the year the
study began. Between September of the first year (month 9) and
February (month 14), creatinine clearance increases significantly but
isotope GFR is constant; thereafter creatinine clearance falls. The lines
represent least squares regressions during the interval shown.
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Fig. 5. Clearances in patient D, plotted as in Figure 2. Creatinine
clearances indicate progression but isotope GFR's do not.
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ances fail to show any progression during this interval. The
reason for the apparent slowing of progression thereafter is
unknown.
Patient H, followed for 22 months (Fig. 7), is progressing
according to both measures, but creatinine clearances yield a
significantly (P < 0.025) more rapid rate of progression than
isotope clearances—more than twice as great, in fact.
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Patient R was studied twice, once on amino acids (Fig. 8) and
once on ketoacids (Fig. 9). During both studies, there was an
interval when creatinine clearances overestimated her rate of
progression, which, according to isotope GFR's, was in fact
statistically insignificant. It should be noted, however, that
different progression rates are obtained only when clearance
observations before and/or after the intervals shown are ig-
nored.
In patient T (Fig. 10), isotope clearances indicate statistically
significant (P < 0.025) improvement while concomitant creati-
nine clearances suggest worsening.
Intervals during which the two clearances yield differing
estimates of progression are likewise intervals during which
Cr/GPR exhibits a progressive change with time, reflecting a
change in tubular secretion of creatinine.
Thus creatinine clearances gave misleading impressions of
progression during all or part of the period of observation in 9 of
these 22 studies.
Part of the variability in creatinine clearances is attributable
to errors in urine collection. To eliminate this source of error
and to determine whether progression rates estimated from the
Discussion
Endogenous creatinine clearance has been employed as a
measure of GFR for 50 years [11], and remains the most widely
used technique for this purpose. For example, Friedman [12]
states, "The endogenous creatinine clearance is a reliable and
reproducible measure of glomerular filtration rate even when
the clearance is less than 10 mi/mm." However, it is now
generally held that CCr exceeds GFR by a large and variable
amount [1—61. The use of measurements of plasma creatinine,
[Cr], to assess the rate of progression of chronic renal failure
received impetus from the observation that [Cr]' tends to
decline linearly with time [13]. Although this would suggest that
CCr also tends to decline linearly with time as creatinine
excretion remains constant, it was also recognized that creati-
nine output falls as renal failure progresses and furthermore
falls when meat intake is restricted 1141. Furthermore, creati-
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Fig. 8. Clearances in patient R during amino acid supplementation.
Progression rate as estimated from creatinine clearances, —1.11 mI/mini
mo, is significantly faster than progression as estimated from isotope
GFR's, —0.384 ml/minlmonth, up to August.
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Fig. 10. Clearances in patient T, plotted as in Figure 2. Isotope GFR's
indicate significant regression of renal insufficiency, but creatinine
clearances do not.
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slope of plasma FCr]' are more reliable, "creatinine' clear-
ances" were calculated as described in Methods. This technique
is preferable to the use of the slope of plasma [Cr]' alone,
because the units of this slope, dl mg' month', are not in
terms of renal function and furthermore, equal slopes in these
units can signify widely differing rates of change of clearance,
when they are multiplied by high or low valUes of urinary
creatinine excretion.
The results are summarized in Table 3. Average m, was
0.105, insignificantly different from 0b2 but significantly (P <
0.02) less than a by paired comparison. Mean b3 was 0.209
0.052 mi/mm/month, similar to b2 but less rapid than b1 by
10 paired comparison (P < 0.05), though not significantly so in any14 16 18 20 22 single study. This is because on the average, urinary creatinine
Months excretion fell progressively, owing to decreasing muscle mass
or, more likely, to increasing extrarenal metabolism of creati-
nine as renal failure became more severe [10]. Rates of progres-
sion estimated from "creatinine1 clearances" differ signifi-
cantly from rates calculated from isotope clearances during all
or part of the observation period in 10 of the 22 studies—for the
most part the same studies depicted in Table 2 and in the
figures. "Creatinine' clearances" overestimated progression
in six studies and underestimated progression in four studies.
Thus this technique of measuring progression is equally mis-
leading.
Fig. 9. Clearances in patient R before (September) and during keto-
acid supplementation, plotted as in Figure 2. From November on,
creatinine clearances indicate progression at —0574 mi/mm/month, but
progression estimated from isotope GFR's, —0.101 mI/mm/month, is
significantly slower.
Walser et al: Creatinine measurements in CRF 417
Table 3. Comparison of progression rates, b, calculated from isotope clearances with those calculated from measurement of reciprocal plasma
creatinine
Pt Rx"
Subperiod Entire period
Isotope clearances Creatinine l clearances Creatinine — clearances
N b b N b 0b N b °'b
A K 20 +0.001 0.033
B K 9 —0.069 0.058
C A 7 0.075
C K! 9 —0.l86 0.061
C K2 7 0.169
D K 20 0.031
E K 7 —0.346 0.094
F A 9 —0.155 O.O39 6 +o.oosa 0.064 7 —0.060 0.055
G A 9 O.338e 0.107
H K 21 0.017
L K 5 —0.2l5 0.046 9 0.026 21 —O.O6l O.009
M A 5 +0.036 0.035 7 —O.l59 0.019 13 O.O9l 0.014
M K 5 +0.075 0.110
0 K 21 —0.l02 0.022
P A 7 —0.744 0.521
R A 5 —0.394 0.138
R K 9 —O.26l' 0.074
S A 12 O.443 0.108
S K 7 —0.130 0.182
T A 12 0.089
U A 4 —0.339 0.101 7 +0.103a 0.130 8 —0.112 0.160
W A 16 —O.424 0.092
x 5.8 —0.168 0.085 7.2 —0.032 0.060 11 —0.209 0.105
a Significantly different from slope of isotope clearance, P < 0.05
b Significantly different from slope of isotope clearance, P < 0.025
C Significantly different from slope of isotope clearance, P < 0.01d Significantly different from zero, P < 0,05
Significantly different from zero, P < 0.025
Significantly different from zero, P < 0.01
Significantly different from entire period, P < 0.01
h K = ketoacids, A = amino acids
'Defined in Table 2
nine production may be affected by other variables, including
exercise, menstruation, and fever [15]. Ccr measurements
should avoid these problems, and indeed, several authors have
reported that CCrfalls linearly with time in chronic renal failure
and have used these slopes as measures of the rate of progres-
sion [7, 16—20]. Despite the discrepancy between CCr and GFR,
it is conceivable that the rate of decline of CCr might be very
close to the true rate of decline of GFR.
Some evidence that this is not the case was presented by
Shemesh et al [4], as summarized earlier. They concluded that
". . . the continued use of creatinine as a sole marker to
monitor GFR in patients with glomerular diseases is no longer
justifiable in a research setting and suboptimal in many clinical
settings".
The present data strengthen this conclusion. In comparison
with sequential measurements of isotope GFR, sequential mea-
surements of Ccr in our hands were inferior for measuring
progression in three ways: (1) they were more variable; (2) they
generally overestimated progression rate; and (3) in nearly half
of the studies, creatinine measurements gave grossly misleading
estimates of the rate (or direction) of progression, during all or
part of the period of observation, because fractional tubular
secretion of creatinine either waxed or waned.
It is clear from Figures 2 to 10 that these discrepancies are not
simply the result of random error. In each of these nine studies,
the ratio of creatinine clearance to GFR undergoes a slowly
progressive change for periods ranging from 4 to 28 months. In
three, the ratio increases, reflecting increased tubular secretion
of creatinine and/or creatinine chromogens, and in the other six,
it decreases, reflecting decreased secretion. In most of the
studies, there is a point in time at which the two clearances
appear to be the same, reflecting zero secretion.
The possibility that these differing slopes are attributable to
changing tubular secretion or reabsorption of the isotope seems
extremely unlikely. Although small differences between the
clearance of DTPA and inulin have been reported [22, 23], there
is no evidence that DTPA can undergo substantial rates of
tubular secretion or reabsorption.
The clinical significance of a progressive increase or decrease
in tubular secretion of creatinine is unknown. Two of the
present patients (patient C, study K2, Fig. 4, and patient D, Fig.
5), in whom creatinine clearances indicated progression but
isotope GFR's did not, went on to dialysis, suggesting that
worsening creatinine clearance in these two patients was a
better measure of clinical outcome. However, a third patient
(R, study K, Fig. 9) continues to do well with constant isotope
GFR despite worsening Ccr and in patient B (Fig. 3) GFR fell
and he required dialysis even though Ccr was constant. Thus in
418 Walser et a!: Creatinine measurements in CRF
these two patients, GFR was a better measure of clinical
Outcome.
It is also worthy of note that creatinine secretion may be
affected by intake of meat versus vegetable protein [24].
Wiegmann et al [25] report that meat ingestion may increase CCr
without altering inulin clearance.
In five studies we selected time intervals during which the
greatest difference between progression rates as determined
from these two clearances was demonstrable. Therefore we
cannot state with assurance how frequently significant differ-
ences will occur in a random sample of patients, followed for
any particular interval of time. Progressive improvement or
worsening in the completeness of urine collections may also
have occurred in individual patients. However, Shemesh et al
[4] measured simultaneous clearances and obtained similar
results.
Use of plasma [Cr] — to measure progression reduced vari-
ability and yielded an average rate close to that obtained from
isotopic clearances. Evidently the average decrease in tubular
secretion of creatinine was offset by an average decrease in
creatinine excretion. Nevertheless, results obtained by this
technique were no less misleading in individual patients. If meat
intake changed more than it did in the present study, in which
diets were constant, such measurements would be more mis-
leading.
The results establish that sequential creatinine clearances or
sequential values of plasma [Cr] may, in many cases, give
misleading estimates of the rate or existence of progression. We
conclude that measurements of creatinine in plasma or urine
should, when feasible, be replaced by measurements of isotope
GFR (or inulin clearance) in following patients with chronic
renal failure.
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